Scott Stromatt

About

Dr. Stromatt is the Chief Medical Officer at Aptevo Therapeutics, a position he held for the last eight years at Emergent. He leads Clinical Research, Medical Affairs, Pharmacovigilance, and Regulatory Affairs, and the clinical development programs for the ADAPTIR molecules that he designed. Dr. Stromatt has nearly three decades of experience at biotechnology and pharmaceutical companies, including being a biotechnology analyst for Wall Street investment firm C.E. Unterberg. Dr. Stromatt has conducted over 55 clinical trials in a wide variety of indications, including oncology, rheumatology, pulmonology, gastroenterology, and neurology.

Investment Focus

Location

Seattle, US